Global rise in penis cancer—what you need to know
Penis cancer is thankfully rare, but cases are rising. Some experts predict a 77% increase in penis cancer by 2050.
Jul 3, 2024
0
1
Penis cancer is thankfully rare, but cases are rising. Some experts predict a 77% increase in penis cancer by 2050.
Jul 3, 2024
0
1
Attention sunscreen skeptics: The sun's UV rays are coming for you, and you're just making their job easier.
Jul 3, 2024
0
84
New research indicates the inhibitory effects of cAMP responsive element binding protein 3 (CREB3) on hepatocellular carcinoma (HCC) in vitro and in vivo. The paper is published in the journal MedComm.
Jul 3, 2024
0
0
Hepatocellular carcinoma (HCC), a leading cause of cancer-related mortality globally, exhibits a dismal five-year survival rate of only 18%. Major contributing factors to HCC include viral hepatitis infections and nonalcoholic ...
Jul 2, 2024
0
0
Among patients with incompletely excised basal cell carcinoma (BCC), only about 16% with positive histopathologic margins have clinical recurrence, according to a study published online June 13 in Dermatology.
Jul 1, 2024
0
0
An international research team has demonstrated a method to identify the cells in the immune system that can recognize and fight cancer cells in samples from 9 out of 10 patients affected by the rare but aggressive form of ...
Jul 1, 2024
0
5
Researchers at the Optics and Photonics Research Center (CePOF) in Brazil and collaborators at the University of Toronto and Princess Margaret Cancer Center in Canada have reported for the first time the effective use of ...
Jun 27, 2024
0
26
Eligibility requirements for clinical trials help protect patients whose comorbidities may put them at an additional risk of severe harm from the treatment being tested. Further, they help ensure that analyses are performed ...
Jun 27, 2024
0
0
A study led by clinician-scientists and scientists from the National Cancer Centre Singapore (NCCS) and A*STAR's Genome Institute of Singapore (GIS) has discovered unexpected molecular heterogeneity even within the same liver ...
Jun 24, 2024
0
0
The U.S. Food and Drug Administration has approved Merck's Keytruda (pembrolizumab) plus chemotherapy as treatment for adult patients with primary advanced or recurrent endometrial carcinoma. This is the third FDA-approved ...
Jun 24, 2024
0
0